Abstract:e16109 Background: Neoadjuvant immune checkpoint inhibitors (ICIs) have shown certain effectiveness in resectable gastric cancer (GC), but the efficacy of conversion ICIs in initially unresectable locally advanced or oligometastatic GC is unclear, particularly regarding efficacy prediction and drug resistance mechanisms through multi-omics analysis. Methods: This is a single-arm, retrospective real-world study to evaluate the efficacy of ICI-containing neoadjuvant/conversion treatment for patients with unresectable locally advanced or oligometastatic GC. Primary endpoints included complete pathological response (pCR) rate, major pathological response (MPR) rate, and R0 resection rate. Secondary endpoints were overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and safety. Exploratory endpoint was the correlation between tumor genetic characteristics and treatment efficacy. Results: Of the 73 included patients, including 64.4% stage cIVa and 10.9% cIVb, 60 (82.2%) underwent radical surgery after conversion combination treatment. The pCR and MPR rates were 28.6% (95% CI 17.1–40.0%), 42.9% (95% CI 30.3–55.4%), with median DFS/PFS at 30.9 (95% CI 16.0-NA) and mOS at 41.3 (95% CI 23.9-NA) months. The stage IV patients achieved 76.4% R0 resection rate, 24.4% pCR rate, and 40.0% MPR rate, with significantly longer OS for R0 patients versus non-R0 ones (HR: 0.22, 95% CI 0.07-0.70, P = 0.0002), and 1-year OS rate 95.2% vs. 64.2%, the 2-year OS rates 71.1% vs. 9.2%, respectively. Even the mOS of stage IV nonMPR patients are significantly prolonged than that of nonR0 ones, indicating that the implementation of R0 surgery was more crucial than MPR. For stage IV patients of R0-MPR, R0-nonMPR and nonR0, the the 3-year OS rates were 85.0%, 51.3%, and near 0, respectively. Subgroup analysis identified significant correlations between pathological responses and pathological type, PD-L1 expression, and tumor mutational burden. The toxicity and post-surgery complications were manageable. Multi-omics analysis revealed that KMT2D mutations were associated with improved clinical outcomes and enhanced immune responses, while tumor cytochrome P450 was linked to treatment resistance. Additionally, an efficacy-predictive model PEMIT was established using an 8-gene panel and was confirmed to surpass common biomarkers such as PD-L1, tumor mutational burden, and mismatch repair status. Conclusions: ICIs-based neoadjuvant/conversion therapy demonstrated promising survival benefits and acceptable safety profiles for patients with unresectable locally advanced and oligometastatic GC, providing a valuable treatment option for this population. Multi-omics findings uncovered mechanisms of drug resistance and provided potential efficacy-related biomarkers.

A single-arm, multi-center phase II study of tislelizumab combined with lenvatinib and GEMOX as conversion therapy in potentially resectable locally advanced biliary tract cancer (ZSAB-TransGOLP): A primary analysis.

Lenvatinib Plus PD-1 Inhibitors As First-Line Treatment in Patients with Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study

A phase II study of anlotinib combined with temozolomide in the treatment of patients with recurrent glioblastoma.

Efficacy and safety of tislelizumab combined with lenvatinib and FOLFOX4-HAIC in conversion therapy of middle-advanced stage hepatocellular carcinoma (HCC): A real-world retrospective study.

162P Efficacy and Safety of GEMOX (gemcitabine Plus Oxaliplatin) Plus Sintilimab and Bevacizumab As a Conversion Therapy in Patients with Initially Unresectable Biliary Tract Cancers (BTC): A Single-Arm, Phase II Study

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial

Sintilimab plus lenvatinib as conversion therapy in patients with unresectable locally intermediate to advanced hepatocellular carcinoma: A single-arm, single-center, open-label, phase 2 study.

Successful conversion surgery for locally advanced gallbladder cancer after gemcitabine and nab-paclitaxel chemotherapy

FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study

Immuno-based conversion therapy for survival in initially unresectable locally advanced or oligometastatic gastric cancer: A retrospective real-world study with multi-omics analysis.

A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma

mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial

Tislelizumab Combined with Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric Carcinoma: Preliminary Results of a Single-Arm, Open-Label Phase I/IIa Trial (TALENT Study).

A Phase II Study of Anti–pd-1 Antibody Camrelizumab Plus FOLFOX4 or GEMOX Systemic Chemotherapy As First-Line Therapy for Advanced Hepatocellular Carcinoma or Biliary Tract Cancer.

Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors

1584P Conversion Effect of PD-1 Antibody Camrelizumab (cam) Combined with Modified FLOT (mflot) Regimen in Patients(pts) with Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial

SOX combined with tislelizumab and low-dose radiation therapy for the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase Ib/II clinical trial

Fruquintinib Combined with Sintilimab and SOX As Conversion Therapy for Unresectable Locally Advanced or Metastatic Gastric/gastroesophageal Junction Adenocarcinoma (GC/GEJC): A Single-Arm, Open-Label, Phase 2 Clinical Trial.

Conversion chemotherapy with capecitabine and oxaliplatin for colorectal cancer with potentially resectable liver metastases: A phase II, open-label, single-arm study.

P-110 Safety and Efficacy of GEMOX Plus Donafenib and Tislelizumab As First-Line Therapy for Advanced Epithelial Malignant Biliary Tract Cancer